Transplant eligibility in elderly multiple myeloma patients: Prospective external validation of the international myeloma working group frailty score and comparison with clinical judgment and other comorbidity scores in unselected patients aged 65‐75 years
- 3 April 2020
- journal article
- research article
- Published by Wiley in American Journal of Hematology
- Vol. 95 (7), 759-765
- https://doi.org/10.1002/ajh.25797
Abstract
Autologous stem cell transplantation (ASCT) is feasible and effective in selected older patients with Multiple Myeloma but specific criteria for evaluating ASCT eligibility in elderly patients are lacking. We evaluated 131 patients aged 65‐75 considered for ASCT at our center: Charlson Comorbidity Index (CCI), Hematopoietic cell transplantation comorbidity index (HCT‐CI) and IMWG frailty score were obtained at diagnosis, but the intensity of treatment was left to physician's choice. The scores and age's impact on outcome was analyzed: 85 patients were judged transplant eligible, whereas 46 patients received a less intensive treatment (median follow up 27 months). No patients classified as FRAIL had been considered eligible to ASCT with a worse outcome compared to FIT and UNFIT patients (median PFS: 7,9 vs 32,9 and 29,6 months; p<0.0001). PFS was superior in the ASCT group (35,6 vs 19,9 months, p0,013). In the ASCT group, PFS was better in patients aged 65‐69 years than in patients ≥70 (51,5 vs 27,7 months, p 0,0037). Indeed, in UNFIT patients aged ≥70 the PFS of the ASCT group was comparable to NO ASCT group (18 vs 27 months, p 0,33) whereas in UNFIT patients aged 65‐69 PFS was superior in the ASCT group: 43,3 vs 18,4 months, p 0.01. ISS III and impaired functional status independently affected PFS in a multivariate analysis (p 0.011 and p 0.006). While CCI and HCT‐CI did not predict different outcome in ASCT patients, the IMWG frailty score would be of help in identifying UNFIT patients aged 70‐75 whose outcome with ASCT selected by clinical judgment was no better than with less intensive treatmentsKeywords
This publication has 36 references indexed in Scilit:
- N‐terminal fragment of the type‐B natriuretic peptide (NT‐proBNP) contributes to a simple new frailty score in patients with newly diagnosed multiple myelomaAmerican Journal of Hematology, 2016
- Geriatric assessment in multiple myeloma patients: validation of the International Myeloma Working Group (IMWG) score and comparison with other common comorbidity scoresHaematologica, 2016
- Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group reportBlood, 2015
- Survival of Multiple Myeloma Patients Aged 65-70 Years in the Era of Novel Agents and Autologous Stem Cell TransplantationActa Haematologica, 2014
- Autologous stem cell transplantation for elderly patients with newly diagnosed multiple myeloma in the era of novel agentsAnnals of Oncology, 2014
- Autologous stem cell transplantation in patients of 70 years and older with multiple myeloma: Results from a matched pair analysisAmerican Journal of Hematology, 2008
- Impact of age and serum creatinine value on outcome after autologous blood stem cell transplantation for patients with multiple myelomaBone Marrow Transplantation, 2007
- High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for Multiple MyelomaThe New England Journal of Medicine, 2003
- Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 yearsBritish Journal of Haematology, 2001
- A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple MyelomaThe New England Journal of Medicine, 1996